Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 2092 of 6351
-
Can a donor corneal disc heal scarred eyes from herpes?
Disease control By invitation onlyThe aim of this study is the evaluation of corneal transparency and improvement of visual acuity in patients with herpetic stromal keratitis.
Sponsor: Eye Hospital Pristina Kosovo • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New drug hope for scleroderma patients with lung complications
Disease control OngoingThe purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).
Phase 2 • Sponsor: Cumberland Pharmaceuticals • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Cancer drug shows promise for Parkinson's in small trial
Disease control CompletedParkinson's disease (PD) is the second most common neurodegenerative disorder causing motor and non-motor symptoms. PD is characterized by death of dopaminergic (DA) neurons in the substantia nigra (SN) pars compacta and formation of inclusions known as Lewy bodies (LBs) that pri…
Phase 2 • Sponsor: Georgetown University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Kickoff for heart health: can casual football get inactive men fit?
Prevention CompletedThe aim of this study was to examine the health and physical fitness effects of 12 weeks of recreational football in inactive 30-50-year-old men. This was a two-arm, parallel-group randomized controlled trial with a 1:2 allocation ratio to either a control group, which was inform…
Sponsor: University of Southern Denmark • Aim: Prevention
Last updated Sep 06, 2026 00:00 UTC
-
Can a global registry map the path to better outcomes for alpha thalassemia?
Knowledge-focused Recruiting nowThis is an international prospective registry of patients with Alpha thalassemia to understand the natural history of the disease and the outcomes of fetal therapies, with the overall goal of improving the prenatal management of patients with Alpha thalassemia.
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Can we decode the hidden food allergies that Don't show up on standard tests?
Knowledge-focused Recruiting nowNon-IgE-mediated gastrointestinal food allergies (non-IgE-GIFA) are an evolving web of clinical conditions characterized by subacute and/or chronic symptoms and include food protein-induced enterocolitis syndrome (FPIES), food protein-induced enteropathy (FPE), food protein-induc…
Sponsor: Federico II University • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Could a single injection transform hip replacement recovery?
Symptom relief CompletedHip replacement surgery is one of the most common elective surgeries in Canada and with this surgery, there is considerable pain after the operation. By decreasing the amount of pain after surgery, the patients may be able to move and walk quicker, resulting in easier physiothera…
Sponsor: McMaster University • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Shock therapy for PTSD? brain stimulation shows promise in new trial
Symptom relief CompletedPost-Traumatic Stress Disorder (PTSD) is an anxiety disorder that can develop after exposure to a terrifying event or ordeal in which there was the potential for or actual occurrence of grave physical harm. Traumatic events that may trigger PTSD include violent personal assaults,…
Sponsor: University Hospital, Tours • Aim: Symptom relief
Last updated Jun 27, 2026 08:06 UTC
-
New hope for rare blau syndrome: tofacitinib under the microscope
Disease control By invitation onlyTo investigate the effectiveness of the JAK 1/3 inhibitor tofacitinib in treating Blau syndrome and explore the association between various clinical and genetic features and therapeutic responses within the cohort.
Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Brain scan study seeks suicide risk biomarker
Knowledge-focused CompletedThe ultimate aim of this study is to identify a biomarker of suicide risk in MDD by measuring the "hedonic spectrum" (pain and reward responsivity), attention and its associated brain structures using brain scans (fMRI and DTI), as well as the stability of markers over time.
Sponsor: Unity Health Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Stepping up stroke recovery: could intensive walking practice boost rehabilitation?
Disease control OngoingThe purpose of this quality improvement project was first to monitor usual physical therapy care (types \& cardiovascular intensity of interventions and amount of stepping practice provided) and outcomes. Following which educational training and support was provided to treating p…
Sponsor: Indiana University • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Simple urine test could replace painful scope for bladder cancer detection
Diagnosis OngoingTo improve upon the non-invasive detection of BCa by further validating a multiplex ELISA assay directed at a BCa-associated diagnostic signature in voided urine samples of patients with gross hematuria.
Sponsor: Cedars-Sinai Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 09:02 UTC
-
New hope for advanced bladder cancer: BISCAY trial tests multiple drug combos
Disease control OngoingThis is an open label, multi-drug, biomarker-directed, multi-centre, multi-arm, Phase 1b study in patients with muscle invasive bladder cancer (MIBC) (urothelial) who have progressed on prior treatment. This study is modular in design, allowing evaluation of the safety, tolerabil…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New drug bimekizumab shows promise for psoriasis in early trial
Disease control CompletedThis is a Phase 2a, multicenter, randomized, subject-blind, investigator-blind, study to investigate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis
Phase 2 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New combo therapy targets tough lung cancer
Disease control CompletedThe purpose of this study is to evaluate the safety and tolerability of itacitinib in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Phase 1/2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Neck surgery before Chemo-Radiation may reduce side effects in head and neck cancer patients
Disease control CompletedTreatment of regionally-advanced head and neck squamous cell carcinoma (HNSCC) requires a multidisciplinary approach with a combination of surgery, radiotherapy (RT) and chemotherapy. Due to these aggressive combined modalities, patients undergoing treatment and many survivors de…
Phase 3 • Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
MRI-Guided radiation may spare healthy organs in gynecologic cancer treatment
Disease control Recruiting nowThis research is being done to evaluate multimodality imaging, including magnetic resonance imaging-guided therapy (MRT), as a possible treatment for gynecologic cancers. The therapy takes place in the Department of Radiation Oncology at the Johns Hopkins SKCCC. The purpose of th…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New triple inhaler shows promise for better breathing in COPD
Disease control CompletedPrimary Objective • To demonstrate the superiority of CHF 5993 pressurised metered dose inhaler (pMDI) over Symbicort® Turbuhaler® in terms of pulmonary function (change from baseline in pre-dose morning forced expiratory volume in the first second of a forced vital capacity man…
Phase 3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New combo therapy shows promise for hard-to-treat lung cancer
Disease control CompletedThis phase II trial studies how well TG4010 and nivolumab work in previously treated patients with non-small cell lung cancer. Vaccines that are made from a gene-modified virus, such as TG4010, may help the body build an effective immune response to kill tumor cells. Monoclonal a…
Phase 2 • Sponsor: Megan Daly, MD • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New targeted drug shows promise for Hard-to-Treat cancers
Disease control OngoingThis is an open-label, multicenter, Phase I study designed to evaluate the safety, tolerability, and pharmacokinetics of inavolisib administered orally as a single agent in patients with locally advanced or metastatic PIK3CA-mutant solid tumors, including breast cancer, and in co…
Phase 1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Sep 09, 2026 23:00 UTC